Mr. Joseph W. Reilly - President and Chief Executive Officer

Mr. Reilly serves as our President and Chief Executive Officer.

Mr. Reilly is a proven CEO/Entrepreneur who has most recently been involved in a successful start up of a Biotech/Life Sciences company.  He possesses significant skills in strategy development and execution, planning, marketing, sales and operations with significant M&A and turnaround experience.

He is a startup specialist who served as President and CEO of a startup biotech company, Theranostics Health, which included technology spun out of George Mason University.

Previously, he served as Managing Director of The Chatham Group, LLC where he advised numerous private equity firms and financial buyers on acquisitions of energy and infrastructure-related assets and companies.

He also served as the President and CEO of a market leading composite technologies company which designed, developed and marketed innovative composite products to the utility and telecommunications industries.  Previously, he was the President of a privately-owned international manufacturing business.
In the 1980’s, Mr. Reilly was an executive and investor in three Forstmann Little & Co. leveraged buyouts: Lear Seigler Corp., Midland Ross Corp. and F.L. Industries, having a combined transaction value in excess of $4 billion.

Mr. Reilly is a Certified Public Accountant.  He received a BS in Accounting and an MBA from St. John’s University and is the former Mayor of Chatham Township, New Jersey.

Cato T. Laurencin, M.D., Ph.D. – Scientific Founder

Dr. Laurencin, M.D., Ph.D., is Chief Executive Officer of the Connecticut Institute for Clinical and Translational Science, Director of the Institute for Regenerative Engineering and the Van Dusen Endowed Chair in Orthopaedic Surgery.

He previously served as the UConn Health Center’s Vice President for Health Affairs and Dean of the UConn School of Medicine. Prior to his arrival at the UConn Health Center, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and chair of the Department of Orthopaedic Surgery at the University of Virginia, as well as the Orthopaedic Surgeon-in-Chief at the University of Virginia Health System. In addition, he was designated as a University Professor at the University of Virginia, one of the university’s most prestigious titles, and held professorships in Biomedical Engineering and Chemical Engineering.

Dr. Laurencin is an expert in shoulder and knee surgery and an international leader in tissue engineering research. He is a Fellow of the American College of Surgeons and the American College of Orthopaedic Surgeons, is widely published in scholarly journals and holds more than 20 U.S. patents.

President Obama named Dr. Laurencin a 2009 winner of the Presidential Award for Excellence, awarded to science, math and engineering mentors. Additionally, Dr. Laurencin was recently honored by Scientific American Magazine as one of the top 50 innovators for his groundbreaking technological work in the regeneration of knee tissue. He was also recently named among “100 Chemical Engineers of the Modern Era” by the American Institute of Chemical Engineers, and is the 2009 winner of the Pierre Galletti Award, the American Institute for Medical and Biological Engineering’s highest honor.

Among his many national responsibilities, Dr. Laurencin has served as Speaker of the House of the National Medical Association, and currently serves as Chair of the Board of the National Medical Association’s W. Montague Cobb Health Institute. He has been a member of the National Institutes of Health National Advisory Council for Arthritis, Musculoskeletal and Skin Diseases and the National Science Advisory Board for the U.S. Food and Drug Administration. He currently sits on the National Science Foundation’s Engineering Directorate Advisory Committee.

Dr. Laurencin earned his B.S.E. in Chemical Engineering from Princeton University, and his M.D. from Harvard Medical School where he graduated Magna Cum Laude and earned the Robinson Award for Excellence in Surgery. Simultaneously he earned a Ph.D. in Biochemical Engineering/Biotechnology from the Massachusetts Institute of Technology where he was a Hugh Hampton Young Scholar.

After completing his doctoral programs, Dr. Laurencin continued clinical training at the Harvard University Orthopaedic Surgery Program, and ultimately became Chief Resident in Orthopaedic Surgery at the Beth Israel Hospital, Harvard Medical School. Simultaneously, he was an instructor in the Harvard–M.I.T. Division of Health Sciences and Technology, where he directed a biomaterials laboratory at M.I.T. Dr. Laurencin subsequently completed a clinical fellowship in Sports Medicine and Shoulder Surgery at the Hospital for Special Surgery in New York, working with the team physicians for the New York Mets, and St. John’s University in New York.
Board certified in orthopaedic surgery, Dr. Laurencin is a Fellow of the American College of Surgeons and a Fellow of the American Academy of Orthopaedic Surgeons. He has lectured throughout the world in the areas of shoulder surgery and biomaterials science as an American British and Canadian Traveling Fellow, and has been an instructor in shoulder surgery at the American Academy of Orthopaedic Surgery’s Orthopaedic Learning Center.

Dr. Laurencin’s research interests are in the areas of biomaterials, tissue engineering, drug delivery and nanotechnology. Honored at the White House, Dr. Laurencin received the Presidential Faculty Fellowship Award from President William Clinton in recognition of his research work involving biodegradable polymers. Dr. Laurencin is a Fellow of the American Institute for Medical and Biological Engineering, and an International Fellow in Biomaterials Science and Engineering. He most recently received the William Grimes Award for Excellence in Chemical Engineering from the American Institute of Chemical Engineers and the Leadership in Technology Award from the New Millennium Foundation. Also, Dr. Laurencin has been elected as a member of the prestigious Institute of Medicine of the National Academy of Sciences for his professional achievement and commitment to service.

He has worked in the development and evaluation of number of orthopaedic products. In addition, he is responsible for work resulting in the commercialization of the first polymer based drug delivery system for the treatment of brain tumors, now called GliadelTM.